A Two-part, Randomised, Double-blind, Placebo-controlled Single and Multiple Ascending Dose Study to Assess Safety, Pharmacokinetics and Pharmacodynamics of Oral HTL0016878 in Healthy Younger Adult and Elderly Subjects With a Randomised, Open-label, Crossover Arm to Assess the Effect of Food on Bioavailability of Oral HTL0016878.
Latest Information Update: 10 Apr 2024
At a glance
- Drugs HTL-0016878 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; First in man
- Sponsors Heptares Therapeutics; Nxera Pharma; Sosei Heptares
- 01 Apr 2024 According to a Nxera Pharma Co., Ltd. media release, Sosei Heptares name changed to Nxera Pharma Co., Ltd.
- 27 Nov 2019 Status changed from recruiting to completed.
- 22 Feb 2019 Planned End Date changed from 1 Sep 2018 to 1 Sep 2019.